Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer
Condition: Lung Cancer Intervention: Biological: AdV-tk (aglatimagene besadenovec) + valacyclovir Sponsors: Advantagene, Inc.; University of Pennsylvania Recruiting - verified April 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Genetics | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Valtrex